financetom
Business
financetom
/
Business
/
TPG Co-Founder David Bonderman Dies at 82
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
TPG Co-Founder David Bonderman Dies at 82
Dec 11, 2024 9:36 AM

12:06 PM EST, 12/11/2024 (MT Newswires) -- TPG (TPG) co-Founder David Bonderman has died at 82, the private equity company said Wednesday.

Price: 69.71, Change: +2.04, Percent Change: +3.01

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Baltimore bridge collision sends vehicles tumbling into water
Baltimore bridge collision sends vehicles tumbling into water
Mar 26, 2024
BALTIMORE, March 26 (Reuters) - A container ship smashed into a four-lane bridge in the U.S. port of Baltimore in darkness on Tuesday, causing it to collapse and sending cars and people plunging into the river below. Rescuers pulled out two survivors, one in a very serious condition, and were searching for more in the Patapsco River after huge spans...
RioCan REIT Offering an Additional $150 million of Series AJ Senior Unsecured Debentures
RioCan REIT Offering an Additional $150 million of Series AJ Senior Unsecured Debentures
Mar 26, 2024
07:22 AM EDT, 03/26/2024 (MT Newswires) -- RioCan Real Estate Investment Trust (REI-UN.TO) overnight Monday said it will issue an additional $150 million principal amount of its 5.470% Series AJ senior unsecured debentures, maturing on March 1, 2030. They will be sold at $100.549 per $100 principal amount, with a re-opening yield of 5.357% and an all-in interest rate for...
Gyre Therapeutics Swings to Fiscal 2023 Net Loss, Revenue Rises
Gyre Therapeutics Swings to Fiscal 2023 Net Loss, Revenue Rises
Mar 26, 2024
07:19 AM EDT, 03/26/2024 (MT Newswires) -- Gyre Therapeutics ( GYRE ) said Tuesday it swung to a fiscal 2023 net loss of $1.41 per diluted share from net income of $0.03 a year earlier. Analyst estimates were not available for comparison. Revenue for the year ended Dec. 31 was $113.5 million, up from $102.3 million a year earlier. ...
Eli Lilly's Zepbound Set to Be Key 2024 Revenue Maker as Weight-Loss Drug Usage Surges
Eli Lilly's Zepbound Set to Be Key 2024 Revenue Maker as Weight-Loss Drug Usage Surges
Mar 26, 2024
07:22 AM EDT, 03/26/2024 (MT Newswires) -- Eli Lilly and Company's ( LLY ) weight-loss drug Zepbound is set to become one of its biggest money makers this year as US regulatory approval opened the door for widespread usage. Zepbound, which has tirzepatide as its active ingredient, brought in $175.8 million in revenue last year. For 2024, that's poised to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved